Literature DB >> 30010207

A Bayesian analysis of small n sequential multiple assignment randomized trials (snSMARTs).

Boxian Wei1, Thomas M Braun1, Roy N Tamura2, Kelley M Kidwell1.   

Abstract

Designing clinical trials to study treatments for rare diseases is challenging because of the limited number of available patients. A suggested design is known as the small n sequential multiple assignment randomized trial (snSMART), in which patients are first randomized to one of multiple treatments (stage 1). Patients who respond to their initial treatment continue the same treatment for another stage, while those who fail to respond are rerandomized to one of the remaining treatments (stage 2). The data from both stages are used to compare the efficacy between treatments. Analysis approaches for snSMARTs are limited, and we propose a Bayesian approach that allows for borrowing of information across both stages. Through simulation, we compare the bias, root-mean-square error, width, and coverage rate of 95% confidence/credible interval of estimators from of our approach to estimators produced from (i) standard approaches that only use the data from stage 1, and (ii) a log-Poisson model using data from both stages whose parameters are estimated via generalized estimating equations. We demonstrate the root-mean-square error and width of 95% confidence/credible intervals of our estimators are smaller than the other approaches in realistic settings, so that the collection and use of stage 2 data in snSMARTs provide improved inference for treatments of rare diseases.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  bias; clinical trial; joint model; mean-square error; rare disease

Mesh:

Year:  2018        PMID: 30010207     DOI: 10.1002/sim.7900

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Design and analysis considerations for utilizing a mapping function in a small sample, sequential, multiple assignment, randomized trials with continuous outcomes.

Authors:  Holly Hartman; Roy N Tamura; Matthew J Schipper; Kelley M Kidwell
Journal:  Stat Med       Date:  2020-10-27       Impact factor: 2.497

Review 2.  Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles.

Authors:  Kelley M Kidwell; Satrajit Roychoudhury; Barbara Wendelberger; John Scott; Tara Moroz; Shaoming Yin; Madhurima Majumder; John Zhong; Raymond A Huml; Veronica Miller
Journal:  Orphanet J Rare Dis       Date:  2022-05-07       Impact factor: 4.303

3.  Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis.

Authors:  Yan-Cheng Chao; Howard Trachtman; Debbie S Gipson; Cathie Spino; Thomas M Braun; Kelley M Kidwell
Journal:  Contemp Clin Trials       Date:  2020-03-19       Impact factor: 2.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.